New Drug Development Services
Humanized model of the immune system
The humanized immune system model is an advanced technology that reconstructs the human immune system in mice by transplanting human immune cells or precursor cells into the mouse body. Our company offers two main types of humanized immune system models.Model: PBMC model and CD34+ HSC model.
Our PBMC model: Next-generation technology
We have conducted in-depth research and iterations on the PBMC model, creating the next-generation PBMC model with the following unique advantages:
•High stability: Our PBMC model achieves stable reconstruction of the immune system, with the success rate of experimental modeling increasing from 50% to 87%. At the same time, the intra-group coefficient of variation has significantly decreased from 120% to 20%.
•Multicellular reconstruction: Our PBMC model is industry-leading and can reconstruct various immune cells, including T cells, B cells, NK cells, macrophages, and DC cells.
•Close to human concentration: The number of immune cells reconstructed in our PBMC model can reach or approach the concentration of human immune cells, providing a more realistic environment for drug testing.
Sub-platforms tailored for tumor immunotherapy development
According to different application needs, we provide the following sub-platforms for our clients:
•iHuPBMC-T: Specifically designed for T cell immunotherapy.
•iHuPBMC-NK: Capable of reconstructing NK cells at a clinical level, suitable for NK cell therapy.
•iHuPBMC-B: Can reconstruct B lymphocytes with antibody secretion function, suitable for B cell therapy.
•iHuPBMC-MHC/KO: Modeling on MHC molecule knockout mice, the onset time of GVHD can be delayed by more than 50%.
•iHuPBMC-OncVax: Myeloid cells and lymphoid cells are reconstructed together, suitable for the development of immunotherapies that require antigen presentation, such as tumor vaccines.
As an industry leader in humanized immune system models, we are committed to providing our clients with the highest quality services and solutions. We look forward to cooperating with you to jointly create a new era in tumor immunotherapy development.